As of December 19 at 3:00:00 PM EST. Market Open.
Breakdown
TTM
Operating Expense
13.9300
Operating Income
-13.9300
Net Non Operating Interest Income Expense
-6.1650
Pretax Income
-20.0950
Net Income Common Stockholders
-20.0950
Diluted NI Available to Com Stockholders
-20.0950
Basic EPS
-0.01
Diluted EPS
-0.01
Basic Average Shares
3,707.5000
Diluted Average Shares
3,707.5000
Total Operating Income as Reported
-13.9300
Total Expenses
13.9300
Net Income from Continuing & Discontinued Operation
-20.0950
Normalized Income
-20.0950
Interest Expense
6.1650
Net Interest Income
-6.1650
EBIT
-13.9300
EBITDA
-13.9300
Net Income from Continuing Operation Net Minority Interest
-20.0950
Normalized EBITDA
-13.9300
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
INNMF Amplia Therapeutics Limited
0.0550
-21.43%
2696.HK Shanghai Henlius Biotech, Inc.
23.900
+0.21%
EFTR eFFECTOR Therapeutics, Inc.
0.0002
0.00%
FENC Fennec Pharmaceuticals Inc.
5.97
+2.23%
CLYM Climb Bio Inc
1.9700
+1.03%
ZIVO ZIVO Bioscience, Inc.
16.95
-3.69%
INDP Indaptus Therapeutics, Inc.
0.9200
+3.37%
ACHL Achilles Therapeutics plc
0.9700
-1.61%
AKTX Akari Therapeutics, Plc
0.9760
-2.40%
SYRE Spyre Therapeutics, Inc.
24.33
+5.19%